A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Stephen Salloway(Providence College), Michael Grundman(University of San Diego), Nick C. Fox(NIHR Queen Square Dementia Biomedical Research Unit), Kaj Blennow(Sahlgrenska University Hospital), Murray A. Raskind(University of Washington), E. Liu(Sahlgrenska University Hospital), Rachelle S. Doody(Baylor College of Medicine), Ivan Lieberburg(Sunesis (United States)), Jerome Barakos(California Pacific Medical Center), Christopher H. van Dyck(Yale University), Marwan N. Sabbagh(Cleveland Clinic), Ronald S. Black(Pfizer (United States)), S. Gilman(Sahlgrenska University Hospital), Dale Schenk(Athena Group (United States)), K. M. Gregg(Sahlgrenska University Hospital), Reisa A. Sperling(Harvard University), Ruth A. Mulnard(University of California, Irvine), Lawrence S. Honig(Columbia University)
Cited by 739
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Lecanemab in Early Alzheimer’s Disease
|New England Journal of Medicine|2022|5k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k